Investment Analysts’ Recent Ratings Updates for Cellebrite DI (CLBT)

A number of research firms have changed their ratings and price targets for Cellebrite DI (NASDAQ: CLBT):

• 8/16/2024 – Cellebrite DI had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $15.00 to $18.00. They now have a “buy” rating on the stock.
• 8/16/2024 – Cellebrite DI had its price target raised by analysts at Bank of America Co. from $13.00 to $17.00. They now have a “buy” rating on the stock.
• 8/16/2024 – Cellebrite DI had its price target raised by analysts at Lake Street Capital from $13.50 to $17.00. They now have a “buy” rating on the stock.
• 8/16/2024 – Cellebrite DI had its price target raised by analysts at Craig Hallum from $16.00 to $20.00. They now have a “buy” rating on the stock.
• 8/16/2024 – Cellebrite DI had its price target raised by analysts at Needham & Company LLC from $14.00 to $17.00. They now have a “buy” rating on the stock.
• 8/14/2024 – Cellebrite DI had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $15.00. They now have an “overweight” rating on the stock.

Cellebrite DI Stock Down 2.1 %

Shares of NASDAQ CLBT traded down $0.37 during mid-day trading on Wednesday, reaching $17.03. 739,609 shares of the company were exchanged, compared to its average volume of 1,142,971. The company’s 50 day moving average price is $13.32 and its 200 day moving average price is $11.95. The stock has a market capitalization of $3.51 billion, a PE ratio of -29.36, a PEG ratio of 1.75 and a beta of 1.50. Cellebrite DI Ltd. has a 52 week low of $6.36 and a 52 week high of $17.48.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 15th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The business had revenue of $95.70 million during the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 earnings per share. On average, sell-side analysts predict that Cellebrite DI Ltd. will post 0.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CLBT. Quadrature Capital Ltd acquired a new position in shares of Cellebrite DI in the 4th quarter valued at $2,222,000. Capstone Investment Advisors LLC acquired a new position in Cellebrite DI in the 1st quarter valued at $870,000. Sei Investments Co. lifted its holdings in Cellebrite DI by 44.7% in the 1st quarter. Sei Investments Co. now owns 121,166 shares of the company’s stock valued at $1,343,000 after purchasing an additional 37,408 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in Cellebrite DI by 7.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 7,086,158 shares of the company’s stock worth $56,446,000 after purchasing an additional 514,858 shares during the last quarter. Finally, Inspire Investing LLC purchased a new stake in Cellebrite DI during the 1st quarter valued at about $862,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.